推

UCB's two innovative drugs included in national medical insurance catalog, helping patients with autoimmune and neurological diseases share the benefits of innovation

LongbridgeAII'm LongbridgeAI, I can summarize articles.

On November 14, 2026, the National Healthcare Security Administration officially announced the "National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalog (2026)" (hereinafter referred to as the National Healthcare Catalog). Two self-developed innovative drugs from the Belgian biopharmaceutical company UCB, Bimzelx® (bimekizumab injection) and Ultomiris® (rozanolixizumab injection), were successfully included in the catalog, achieving comprehensive coverage of their approved indications in China. This inclusion marks a critical step for these two innovative therapies from 'innovative breakthrough' to 'innovative accessibility', and is an important milestone for UCB in accelerating the translation of innovation value into patient value, promoting health equity, and contributing to the Healthy China initiative.

The indications for Bimzelx® included in the National Healthcare Catalog include: adult patients with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to conventional therapy; adult patients with radiographic non-radiographic axial spondyloarthritis (nr-axSpA); adult patients with moderate-to-severe plaque psoriasis (PsO) suitable for systemic therapy or phototherapy; and adult patients with moderate-to-severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic therapy. The indication for Ultomiris® included in the catalog is the combination treatment with conventional therapeutic drugs for adult patients with generalized myasthenia gravis (gMG) positive for acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibodies.

Maria Ma, General Manager of UCB China, stated: "We are greatly encouraged by the successful inclusion of Bimzelx® and Ultomiris® in the National Healthcare Catalog. This not only recognizes the clinical value of these two innovative drugs but also means that a broader range of Chinese patients can access differentiated innovative treatment options in an affordable manner, truly realizing widespread accessibility and health equity. Successful inclusion is not the end, but the beginning. Next, we will collaborate closely with all parties to ensure the implementation of the healthcare policy. 2026 marks the 30th anniversary of UCB's entry into China. We will continue to be patient-centric, ensuring that global innovations with significant clinical value and distinct differentiation benefit more Chinese patients."

As an innovative biopharmaceutical enterprise deeply rooted in immunology and neurotherapy, UCB has always placed patient needs first. Psoriasis, hidradenitis suppurativa, ankylosing spondylitis, radiographic non-radiographic axial spondyloarthritis, and generalized myasthenia gravis are chronic diseases that severely impact quality of life, with some treatment needs remaining unmet. As the world's first approved IL-17A/F bispecific inhibitor, Bimzelx® is currently the only approved IL-17A/F bispecific treatment option in China for ankylosing spondylitis, radiographic non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. In the treatment of psoriasis, Bimzelx® has demonstrated superiority in multiple head-to-head Phase III studies. Ultomiris® is China's first approved FcRn antagonist covering both AChR-positive and MuSK-positive generalized myasthenia gravis. The comprehensive inclusion of the approved indications for these two innovative drugs in the National Healthcare Catalog not only recognizes their clinical value but also highlights the significance of differentiated innovation in addressing unmet clinical needs. With the official implementation of the new healthcare catalog, Bimzelx® and Ultomiris® will accelerate the transition of innovative treatments from 'available' to 'accessible', helping more patients receive long-term, standardized treatment support, and promoting the wider reach of innovative therapies.

Jean-Christophe Tellier, Global CEO of UCB, stated: "2026 coincides with the 30th anniversary of UCB in China. The successful inclusion of Bimzelx® and Ultomiris® in the National Healthcare Catalog not only brings lasting value to a wide range of patients but also serves as strong validation of UCB's strategy in China. As a key strategic pillar in UCB's innovation landscape, China will become an important engine for the group's long-term growth. We will continue to deepen our cultivation of the Chinese market, contributing to China's health future."

H.E. Bruno Angelet, Ambassador of Belgium to China, stated: "2026 marks the 55th anniversary of diplomatic relations between China and Belgium. As a leading global biopharmaceutical innovation country and a crucial hub in the European life sciences sector, Belgium possesses a unique ecosystem integrating excellent research, industrial scale, and mature regulation. Furthermore, it will leverage its professional and efficient pharmaceutical logistics infrastructure to continue playing a key gateway role connecting Europe and even global markets. I am delighted to see that the innovative achievements of Belgian biopharmaceutical companies represented by UCB are making positive contributions to the health and well-being of Chinese patients. I also look forward to further deepening exchanges and cooperation between China and Belgium in the fields of life sciences and healthcare, working together to drive innovation and create more value for patients and society."

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.